

Publications 2002 - 2007

Impact Factor 2003 pour Publications Années 2002-2005

Publications originales

2002

1. The Eurohepygast Study Group (Project leader: F. Mégraud). Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study. *Gut* 2002; 50: 779-785. (IF: 6,170)
2. Broutet, N., Moran, A., Hynes, S., Sakarovitch, C., Mégraud, F. Lewis antigen expression and other pathogenic factors in the presence of atrophic chronic gastritis in a European population. *Journal of Infectious Diseases* 2002; 185: 503-512. (IF: 4,910)
3. Ménard, A., Santos, A., Mégraud, F., Oleastro, M. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with *Helicobacter pylori* resistance to clarithromycin. *Antimicrobial Agents and Chemotherapy* 2002; 46: 1156-1157. (IF: 4,562)
4. Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, P., Jones, R., Axon, A., Graham, D.Y., Tytgat, G., & the European *Helicobacter pylori* Study Group (EHPSG). Current concepts in the management of *Helicobacter pylori* infection – The Maastricht 2-2000 Consensus Report. *Alimentary Pharmacology & Therapeutics* 2002; 16: 167-180. (IF: 3,900)
5. Matysiak-Budnik, T., Heyman, M., Candalh, C., Lethuaire, D., Mégraud, F. *In vitro* transfer of clarithromycin and amoxicillin across the epithelial barrier. *Journal of Antimicrobial Chemotherapy* 2002; 50: 865-872. (IF: 3,490)
6. Salles-Montaudon, N., Dertheil, S., Broutet, N., Gras, N., Monteiro, L., de Mascarel, A., Mégraud, F., Emeriau, J.P. Detecting *Helicobacter pylori* infection in hospitalized frail older patients: the challenge. *Journal of the American Geriatrics Society* 2002; 50: 1674-1680. (IF: 2,878)
7. Chanto, G., Occhialini, A., Gras, N., Alm, R.A., Mégraud, F., Marais, A. Identification of strain-specific genes located outside the plasticity zone in nine clinical isolates of *Helicobacter pylori*. *Microbiology* 2002; 148: 3671-3680. (IF: 2,846)
8. Grignon, B., Tankovic, J., Mégraud, F., Glupczynski, Y., Husson, M.O., Conroy, M.C., Emond, J.P., Loulergue, J., Raymond, J., Fauchère, J.L. Validation of diffusion methods for macrolide susceptibility testing of *Helicobacter pylori*. *Microbial Drug Resistance* 2002; 8: 61-66. (IF: 2,600)
9. Weill, F.X., Margeridon, S., Broutet, N., Le Hello, S., Neyret, C., Mégraud, F. Seroepidemiology of *Helicobacter pylori* infection in Guadeloupe. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2002; 96: 517-519. (IF: 1,693)
10. Nylen, G., Dunstan, F., Palmer, S., Andersson, Y., Bager, F., Cowden, J., Geierl, G., Galloway, Y., Kapperud, G., Mégraud, F., Molbak, K., Petersen, L.R., Ruutu, P. The seasonal distribution of campylobacter infection in nine European countries and New Zealand. *Epidemiology & Infection* 2002; 128: 383-390. (IF: 1,462)

11. Glupczynski, Y., Broutet, N., Cantagrel, A., Andersen, L.P., Alarcon, T., Lopez-Brea, M., Mégraud, F. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of *Helicobacter pylori*. *European Journal of Clinical Microbiology & Infectious Diseases* 2002; 21: 549-552. (IF: 1.386)
12. Lehours, P., Rogues, A.M., Occhialini, A., Boulestreau, H., Gachie, J.P., Mégraud, F. Investigation of an outbreak due to *Alcaligenes xylosoxydans* subspecies *xylosoxydans* by random amplified polymorphic DNA analysis. *European Journal of Clinical Microbiology & Infectious Diseases* 2002; 21: 108-113. (IF: 1,386)
13. Matysiak-Budnik, T., Mégraud, F., Heyman, M. In-vitro transfer of nitazoxanide across the intestinal epithelial barrier. *Journal of Pharmacy and Pharmacology* 2002; 54: 1413-1417. (IF: 1,202)
14. Smith, S., Cantet, F., Angelini, F., Marais, A., Mégraud, F., Bayerdöffer, E., Miehke, S. Discriminatory power of RAPD, PCR-RFLP and Southern Blot analyses of *ureCD* or *ureA* gene probes on *Helicobacter pylori* isolates. *Zeitschrift für Naturforschung* 2002; 57c: 516-521.
15. Mauget-Faÿsse, M., Kodjikian, L., Quaranta, M., Ben Ezra, D., Trepsat, C., Mion, F., Mégraud, F. Rôle de l'*Helicobacter pylori* dans la chorioretinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. *Journal Français d'Ophtalmologie* 2002; 25: 1021-1025.
16. Monteiro, L., Bergey, B., Gras, N., Mégraud, F. Evaluation of the performance of the Helico Blot 2.1 as a tool to get insight in the virulence properties of *Helicobacter pylori* strains. *Clinical Microbiology & Infection* 2002; 8: 676-679.

2003

17. Falush, D., Wirth, T., Linz, B., Pritchard, J.K., Stephens, M., Kidd, M., Blaser, M.J., Graham, D.Y., Vacher, S., Perez-Perez, G.I., Yamaoka, Y., Mégraud, F., Otto, K., Reichard, U., Katzowitsch, E., Wang, X., Achtman, M., Suerbaum, S. Traces of human migrations in *Helicobacter pylori* populations. *Science* 2003, 299:1582-1585. (IF: 23,329)
18. Vacher S., Ménard, A., Bernard, E., Mégraud, F. PCR-restriction fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in *Campylobacter* spp. *Antimicrobial Agents & Chemotherapy* 2003; 47:1125-1128. (IF: 4.562)
19. Avenaud, P., LeBail, B., Marais, A., Mayo, K., Bioulac-Sage, P., Mégraud, F. Natural history of *Helicobacter hepaticus* infection in A/J mice. A model for the study of hepatocarcinogenesis in humans. *Infection and Immunity* 2003, 71:3667-3672. (IF: 4,212)
20. Matysiak-Budnik, T., van Niel G., Mégraud F., Mayo K., Bevilacqua C., Gaboriau-Routhiau V., Moreau MC., Heyman M. Gastric *Helicobacter* infection inhibits development of oral tolerance to food antigens in mice. *Infection and Immunity* 2003, 71:5219-5224. (IF: 4,212)
21. Oleastro, M., Ménard, A., Santos, A., Lamouliatte, H., Barthélémy, C., Monteiro, L., Mégraud, F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in *Helicobacter pylori*. *Journal of Clinical Microbiology* 2003; 41: 397-402. (IF: 3,965)
22. Santos, A., Queiroz, D.M.M., Ménard, A., Marais, M., Rocha, G.A., de Oliveira, C.A., Uzeda, M., Mégraud, F. New pathogenicity marker found in the plasticity region of the

- Helicobacter pylori* genome. Journal of Clinical Microbiology 2003 41:1651-1655.. (IF: 3,965)
23. Broutet, N., Plebani, M., Sakarovitch, C., Sipponen, P., Mégraud, F., Eurohepygast Study Group. Pepsinogen A, pepsinogen C and gastrin as serological markers of atrophic chronic gastritis in European dyspeptics. British Journal on Cancer 2003, 88:1239-1247. (IF: 3,942)
 24. Bergey, B., Marchildon, P., Peacock, J., Mégraud, F. What is the role of serology in assessing *Helicobacter pylori* eradication. Alimentary Pharmacology & Therapeutics 2003 18:635-639. (IF: 3,900)
 25. Broutet, N., Tchamgoué, S., Pereira, E., Lamouliatte, H., Salamon, R., Mégraud, F. Risk factors for failure of *Helicobacter pylori* therapy. Results of an individual data analysis of 2,751 patients. Alimentary Pharmacology & Therapeutics 2003; 17: 99-109. (IF: 3,900)
 26. O'Morain, C., Borody, T., Farley, A., de Boer, W., Dallaire, C., Schuman, R., Piotrowski, J., Fallone, C.A., Tytgat, G., Mégraud, F., Spénard, J. Efficacy and safety of single-triple capsules of bismuth biscalcitrates, metronidazole and tetracycline, given with omeprazole, for the eradication of *Helicobacter pylori*: an international multicentre study. Alimentary Pharmacology & Therapeutics 2003 17:415-420. (IF: 3,900)
 27. Lamouliatte, H., Mégraud, F., Delchier, J.C., Bretagne, J.F., Courillon-Mallet, A., de Korwin, D., Fauchère, J.L., Labigne, A., Fléjou, J.F., Barthélémy, P. Second-line treatment for failure to eradicate *Helicobacter pylori*: a randomized trial comparing four treatment strategies. Alimentary Pharmacology & Therapeutics 2003; 18:791-797. (IF: 3,900)
 28. Leodolter, A., Vaira, D., Bazzoli, F., Schutze, K., Hirschl, A., Mégraud, F., Malfertheiner, P. European multicentre validation trial of two new non-invasive tests for the detection of *Helicobacter pylori* antibodies: urine-based ELISA and rapid urine test. Alimentary Pharmacology & Therapeutics 2003; 18: 927-931. (IF: 3,900)
 29. Lehours, P., Ruskone-Fourmestreaux, A., Lavergne, A., Cantet, F., Mégraud, F. Which test to use to detect *H. pylori* infection in patients with low grade gastric MALT lymphoma ? American Journal of Gastroenterology 2003, 98:291-295. (IF: 3,549)
 30. Marais, A., Bilardi, C., Cantet, F., Mendz, G., Mégraud, F. Characterization of the genes *rdxA* and *frxA* involved in metronidazole resistance in *Helicobacter pylori*. Research in Microbiology 2003 154:137-144. (IF: 1,568)
 31. Aguejoug, O., Mayo, K., Monteiro, L., Malfatti, E., Doutremépuich, C., Mégraud, F. Arterial thrombosis and chronic *Helicobacter pylori* infection in mice. Thrombosis Research 2003;108:245-8. (IF: 1,446)

2004

32. Lehours, P., Dupouy, S., Bergey, B., Richy, F., Zerbib, F., Ruskoné-Fourmestreaux, A., Delchier, J.C., Mégraud, F., Ménard, A. Identification of two genetic markers of *Helicobacter pylori* strains involved in extranodal marginal zone B-cell lymphoma of MALT-type. Gut 2004;53:931-7.. (IF 6.17)
33. Matysiak-Budnik, T., Coffin, B., Lavergne-Slove, A., Sabate, JM., Megraud, F., Heyman ? M. *Helicobacter pylori* increases the epithelial permeability to a food antigen in human gastric biopsies. Am J Gastroenterol. 2004; 99: 225-32. (IF 3,549)

34. Lehours, P., Ménard, A., Dupouy, S., Bergey, B., Richy, F., Zerbib, F., Ruskoné-Fourmestreaux, A., Delchier, J.C., Mégraud, F. Evaluation of the association of nine *Helicobacter pylori* virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. *Infection and Immunity* 2004; 72: 880-888. (IF 4.212)
35. Kauser, F., Khan, A.A., Hussain, M.A., Carroll, I.M., Ahmad, N., Tiwari, S., Shouche, Y., Das, B., Alam, M., Ali, S.M., Habibullah, C.M., Sierra, R., Mégraud, F., Sechi, L.A., Ahmed, N. The *cag* pathogenicity island of *Helicobacter pylori* is disrupted in the majority of patient isolates from different human populations. *Journal of Clinical Microbiology* 2004; 42: 5302-5308. (IF 3.489)
36. Avenaud, P., Castroviejo, M., Claret, S., Rosenbaum, J., Mégraud, F., Ménard, A. Expression and activity of the cytolethal distending toxin of *Helicobacter hepaticus*. *Biochemical and Biophysical Research Communications* 2004; 318: 739-745. (IF 2.946)
37. Angelini, F., Ménard, A., Asencio, C., Marais, A., Mégraud, F. Construction of replicative and integrative plasmids for setting up the *in vivo* expression technology in *Helicobacter pylori*. *Plasmid* 2004; 51: 101-107. (IF 1.573)
38. Mégraud, F., Prouzet-Mauléon, V. Evolution de la résistance des Campylobacters aux antibiotiques en France (1986-2002). *Bulletin Epidémiologique Hebdomadaire* 2004; N° 32-33: 156-158

2005

39. Rocha, M., Avenaud, P., Ménard, A., LeBail, B., Balabaud, C., Bioulac-Sage, P., de Magalhaes Queiroz, D.M., Mégraud, F. Association of *Helicobacter* species with hepatitis C cirrhosis with or without hepatocellular carcinoma. *Gut* 2005; 54: 396-401. (IF 5,883)
40. Schaeferbeke, T., Broutet, N., Zerbib, F., Combe, B., Bertin, P., Lamouliatte, H., Perié, F., Joubert-Collin, M., Mégraud, F. Should we eradicate *Helicobacter pylori* before prescribing an NSAID? Result of a placebo controlled study. *American Journal of Gastroenterology* 2005; 100: 2637-2643 (IF 4,172)
41. Prouzet-Mauléon, V., Hussain, M.A., Lamouliatte, H., Kauser, F., Mégraud, F., Ahmed, N. Pathogen evolution *in vivo* : genome dynamics of two isolates obtained 9 years apart from a duodenal ulcer patient infected with a single *Helicobacter pylori* strain. *Journal of Clinical Microbiology* 2005; 43: 4237-4241. (IF 3,489)
42. Mamelli, L., Prouzet-Mauleon, V., Pages, J.M., Mégraud, F., Bolla, J.M. Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. *Journal of Antimicrobial Chemotherapy* 2005; 56: 491-497. (IF 3,08)
43. Mégraud, F. (au nom de l'European Paediatric Task Force on *Helicobacter pylori*). Comparison of non-invasive tests to detect *Helicobacter pylori* infection in children and adolescents: results of a multicenter European study. *Journal of Pediatrics* 2005; 146: 198-203. (IF 2,913)

44. Pyndiah, S., Ménard, A., Zerbib, F., Mégraud, F. Evaluation of the homologous recombination in *Helicobacter pylori*. *Helicobacter* 2005; 10: 185-192. (IF 2,624)
45. Ménard, S., Laharie, D., Asensio, C., Vidal-Martinez, T., Candalh, C., Rullier, A., Zerbib, F., Mégraud, F., Matysiak-Budnik, T., Heyman, M. *Bifidobacterium breve* and *Streptococcus thermophilus* secretion products enhance T helper 1 immune response and intestinal barrier in mice. *Experimental Biology and Medicine* 2005; 230: 749-756. (IF 2,46)
46. de Mascarel, A., Ruskone-Fourmestreaux, A., Lavergne-Slove, A., Mégraud, F., Dubus, P., Merlio, J.P. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. *Virchows Archiv* 2005; 446: 219-224. (IF 2,357).
47. Vacher S., Ménard, A., Bernard, E., Santos, A., Mégraud, F. Detection of mutations associated with macrolide resistance in thermophilic *Campylobacter* spp. by real-time PCR. *Microbial Drug Resistance* 2005; 11: 40-47. (IF 2,32)
48. Ménard, A., Dachet, F., Prouzet-Mauleon, V., Oleastro, M., Mégraud, F. Development of a real-time Fluorescence Resonance Energy Transfer PCR to identify the main pathogenic *Campylobacter* species. *Clinical Microbiology & Infection* 2005; 11: 281-287. (IF 2,238)
49. Mendz, G.L., Mégraud, F., Korolik, V. Phosphonate catabolism by *Campylobacter* spp. *Archives of Microbiology* 2005; 183: 113-120. (IF 1,989)
50. Bergey, B., Gallian, P., Stuart M., Bolla, J.M., de Micco, P., Mégraud, F. Prévalence de l'infection à *Helicobacter pylori* en Corse. *Gastroentérologie Clinique et Biologique* 2005; 29: 611-612. (IF 0,884).

Impact Factor 2005 pour Publications Années 2006-2007

2006

51. Koletzko, S., Richy, F., Bontems, P., Crone, J., Kalach, N., Monteiro, M.L., Gottrand, F., Celinska-Cedro, D., Roma-Giannikou, E., Oderda, G., Kolacek, S., Urruzuno, P., Martinez Gomez, M.J., Casswall, T., Ashorn, M., Bodanszky, H., Mégraud, F. Prospective multicentre study on antibiotic resistance of *Helicobacter pylori* strains obtained from children living in Europe. *Gut* 2006; 52: 804-806. (IF 7.692)
52. Prouzet-Mauléon, V., Labadi, L., Bouges, N., Ménard, A., Mégraud, F. *Arcobacter butzleri*: underestimated enteropathogen. *Emerging Infectious Disease* 2006; 12: 307-309. (IF 5.308)
53. Salles, N., Ménard, A., Georges, A., Salzman, M., de Ledingen, V., de Mascarel, A., Emérian, J.P., Lamouliatte, H., Mégraud, F. Effects of *Helicobacter pylori* infection on gut appetite peptide expression (leptin, ghrelin) in elderly inpatients. *Journal of Gerontology: Biological Sciences* 2006; 61: 1144-50. (IF 4.369)

54. Oleastro, M., Monteiro, L., Lehours, P., Mégraud, F., Ménard, A. Identification of markers for *Helicobacter pylori* strains isolated from children with peptic ulcer disease by suppressive subtractive hybridization. *Infection & Immunity* 2006; 74: 4064-4074. (IF 3.933)
55. Gallay, A., De Valk, H., Cournot, M., Ladeuil, B., Hemery, C., Castor, C., Bon, F., Mégraud, F., LeCann, P., Desenclos, J.C., the Outbreak Investigation Team. A large multi-pathogen waterborne community outbreak linked to faecal contamination of a groundwater system, France, 2000. *Clinical Microbiology and Infection* 2006; 12: 561-570. (IF 2.679)
56. Duckworth, M., Ménard, A., Mégraud, F., Mendz, G.L. Bioinformatic analysis of *Helicobacter pylori* XGPRTase: a potential therapeutic target. *Helicobacter* 2006; 11: 287-295. (IF 2.584)
57. Bury-Moné, S., Kaakoush, N.O., Asencio, C., Mégraud, F., Thibonnier, M., De Reuse, H., Mendz, G. Is *Helicobacter pylori* a true microaerophile? *Helicobacter* 2006; 11: 296-303. (IF 2.584)
58. Kempf, I., Dufour-Gesbert, F., Hellard, G., Prouzet-Mauléon, V., Mégraud, F. Broilers do not play a dominant role in the *Campylobacter fetus* contamination of humans. *Journal of Medical Microbiology* 2006; 55: 1277-1278. (IF 2.318)
59. Sierra, R., Une, C., Ramirez, V., Gonzalez, M.I., Ramirez, J.R., de Mascarel, A., Barahona, R., Salas-Aguilar, R., Paez, R., Avendano, G., Avalos, A., Broutet, N., Mégraud, F. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. *Clinical & Experimental Medicine* 2006; 6: 72-78. (IF 1.228)
60. Castéra, L., Pedeboscq, A., Rocha, M., LeBail, B., Asencio, C., de Lédighen, V., Bernard, P.H., Laurent, C., Lafon, M.E., Capdepon, M., Couzigou, P., Bioulac-Sage, P., Balabaud, C., Mégraud, F., Ménard, A. Relationship between the presence of *Helicobacter* species in the liver and the severity of HCV-related liver disease : a prospective study. *World Journal of Gastroenterology*. 2006; 12: 7278-7284.
61. Mégraud, F. Resistance to antibiotics in *Helicobacter pylori*: what every consultant should know. In: BMJ Learning, London, 2006 (www.bmjlearning.com).

2007

62. Pyndiah, S., Lasserre, J.P., Ménard, A., Claverol, S., Prouzet-Mauléon, V., Mégraud, F., Zerbib, F., Bonneu, M. Two-dimensional blue native/SDS gel electrophoresis of multiprotein complexes from *Helicobacter pylori*. *Molecular and Cellular Proteomics* 2007; 6: 193-206 (IF 9.876)
63. Gallay, A., Prouzet-Mauléon, V., Kempf, I., Lehours, P., Labadi, L., Camou, C., Denis, M., de Valk, H., Desenclos, J.C., Mégraud, F. *Campylobacter* antimicrobial drug resistance among humans, broiler chickens, and pigs, France. *Emerging Infectious Diseases*. 2007;13:259-66. (IF 5,308)

64. Devi SM, Ahmed I, Francalacci P, Hussain MA, Akhter Y, Alvi A, Sechi LA, Mégraud F, Ahmed N. Ancestral European roots of *Helicobacter pylori* in India. BMC Genomics. 2007;8:284. (IF 4,092)
65. Mamelli, L., Demoulin, E., Prouzet-Mauleon, V., Mégraud, F., Pages, JM., Bolla, JM. Prevalence of efflux activity in low-level macrolide-resistant *Campylobacter* species. Journal of Antimicrobial Chemotherapy. 2007; 59: 327-8 (IF 3,886)
66. Decousser, J.W., Prouzet-Mauléon, V., Bartizel, C., Gin, T., Colin, J.P., Fadel, N., Holler, C., Pollet, J., Mégraud, F. Fatal relapse of a purulent pleurisy caused by *Campylobacter fetus* subsp fetus. Journal of Clinical Microbiology. 2007; 45:2334-6. (IF 3,537)
67. Abdelbaqi, K., Buissonnière, A., Prouzet-Mauléon, V., Gresser, J., Wesley, I., P., Mégraud, F., Ménard, A. Development of a Real-time Fluorescence Resonance Energy Transfer (FRET) PCR to detect *Arcobacter* species. Journal of Clinical Microbiology. 2007 (sous presse). (IF 3,537)
68. Cattoir, V., Nectoux, J., Lascols, C., Deforges, L., Delchier, J.C., Mégraud, F., Soussy, C.J., Cambau, E. Update on fluoroquinolone resistance in *Helicobacter pylori*: new mutations leading to resistance and first description of a *gyrA* polymorphism associated with hypersusceptibility. International Journal of Antimicrobial Agents. 2007;29:389-96. (IF 2,428)
69. Lehours, P., Dupouy, S., Chaineux, J., Ruskoné-Fourmestraux, A., Delchier, J.C., Morgner, A., Mégraud, F., Ménard, A. Genetic diversity for the HpyCII restriction modification system in *Helicobacter pylori*. Research in Microbiology 2007; 158: :265-71. (IF 2.426)
70. Abdelbaqi, K., Ménard, A., Prouzet-Mauléon, B., Bringaud, F., Lehours, P., Mégraud, F. Nucleotide sequence of the *gyrA* gene of *Arcobacter* species and characterization of human ciprofloxacin-resistant clinical isolates. FEMS Immunology and Medical Microbiology. 2007; 49: 337-45. (IF 2.371)
71. Laharie, D., Ménard, S., Asencio, C., Vidal-Martinez, T., Rullier, A., Zerbib, F., Candalh, C., Mégraud, F., Heyman, M., Matysiak-Budnik, T. Effect of rebamipide on the colonic barrier in interleukin 10 deficient mice. Digestive Diseases and Sciences. 2007; 52 :84-92 (IF 1.388)
72. Ahmed, N., Majeed, A.A., Ahmed, I., Hussain, M.A., Alvi, A., Devi, S.M., Rizwan, M., Ranjan, A., Sechi, L.A., Mégraud, F. genoBASE pylori: A genotype search tool and database of the human gastric pathogen *Helicobacter pylori*. Infection, Genetics and Evolution. 2007;7:463-8.